logo

Taysha Gene Therapies, Inc. (TSHA)



Trade TSHA now with
  Date
  Headline
11/8/2022 7:19:13 AM Taysha Gene Therapies Q3 Net Loss $26.3 Mln Or $0.64/Shr Vs Loss Of $51.2 Mln Or $1.35/Shr Last Year
10/26/2022 8:16:28 PM Taysha Gene Therapies Prices Underwritten Public Offering Of 14 Mln Shares At $2.00/shr
3/31/2022 7:15:28 AM Taysha Gene Therapies Q4 Net Loss $50.4 Mln Or $1.32/Shr Vs Loss Of $18.3 Mln Or $0.50/Shr Last Year
1/31/2022 7:13:44 AM Taysha Reports Positive Data For High Dose Cohort And Long-term Data For TSHA-120 In Giant Axonal Neuropathy
11/10/2021 7:13:44 AM Taysha Gene Therapies Q3 Net Loss $51.2 Mln Or $1.35/shr Vs Loss Of $15.0 Mln Or $1.28/Shr Last Year
9/29/2021 7:07:33 AM Taysha Gene Therapies Receives Orphan Drug Designation From EU For TSHA-101 For Infantile GM2 Gangliosidosis
9/29/2021 7:06:36 AM Taysha Gets Orphan Drug Designation From European Commission For TSHA-101 For Infantile GM2 Gangliosidosis
9/22/2021 7:10:28 AM Taysha Gets Orphan Drug Designation From European Commission For TSHA-102 For Rett Syndrome
8/25/2021 7:05:46 AM Taysha Gene Therapies Granted Orphan Drug Designation From European Commission For TSHA-105 For Epilepsy
8/16/2021 7:12:52 AM Taysha Gene Therapies Q2 Net Loss $40.9 Mln Or $1.09/Shr Vs Loss Of $21.2 Mln Or $1.95/Shr Last Year
6/21/2021 7:23:48 AM Taysha Gene Therapies Announces Publication Of Natural History Data For TSHA-120 In GAN In The Journal, Brain
5/13/2021 7:16:05 AM Taysha Gene Therapies Names Mary Newman As Chief Development Officer
5/11/2021 7:12:22 AM Taysha Gene Therapies Q1 Net Loss $32.0 Mln Or $0.87/Shr Vs Loss Of $5.4 Mln Or $0.50/Shr Last Year
4/12/2021 7:19:35 AM Taysha Gene Therapies Acquires Exclusive Worldwide rights To Clinical-stage AAV9 Gene Therapy Program
3/9/2021 7:12:13 AM Taysha Gene Therapies Announces Multi-year Collaboration To Advance Mini-gene Payloads For AAV Gene Therapies
3/3/2021 7:29:25 AM Taysha Gene Therapies FY Net Loss $60.0 Mln Or $3.40/Shr Vs Loss Of $1.1 Mln Or $0.12/Shr Last Year